About Revelation Biosciences, Inc.
https://www.revbiosciences.comRevelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease.
CEO
James Rolke
Compensation Summary
(Year )
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
LINDEN ADVISORS LP
Shares:338.11K
Value:$2.77K
CLEAR STREET LLC
Shares:247.58K
Value:$2.03K
CLEAR STREET GROUP INC.
Shares:247.43K
Value:$2.03K
Summary
Showing Top 3 of 17
About Revelation Biosciences, Inc.
https://www.revbiosciences.comRevelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.94M ▼ | $-1.91M ▲ | 0% | $-1.77 ▲ | $-1.9M ▲ |
| Q2-2025 | $0 | $2.46M ▲ | $-2.44M ▼ | 0% | $-7.01 ▼ | $-2.45M ▼ |
| Q1-2025 | $0 | $2.09M ▲ | $-2.05M ▼ | 0% | $-2.11 ▲ | $-2.09M ▼ |
| Q4-2024 | $0 | $1.75M ▼ | $-1.73M ▲ | 0% | $-4.98 ▲ | $-1.75M ▲ |
| Q3-2024 | $0 | $1.8M | $-2.24M | 0% | $-13.38 | $-1.79M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $12.71M ▲ | $12.86M ▲ | $1.85M ▲ | $11M ▲ |
| Q2-2025 | $5.17M ▲ | $5.4M ▲ | $1.57M ▲ | $3.83M ▲ |
| Q1-2025 | $3.7M ▼ | $3.97M ▼ | $1.09M ▼ | $2.88M ▼ |
| Q4-2024 | $6.5M ▼ | $6.62M ▼ | $1.91M ▼ | $4.71M ▲ |
| Q3-2024 | $6.54M | $6.74M | $4.07M | $2.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.91M ▲ | $-1.59M ▲ | $0 | $9.12M ▲ | $7.53M ▲ | $-1.59M ▲ |
| Q2-2025 | $-2.44M ▼ | $-1.92M ▲ | $0 | $3.39M ▲ | $1.47M ▲ | $-1.92M ▲ |
| Q1-2025 | $-2.05M ▼ | $-2.79M ▲ | $0 ▼ | $0 ▼ | $-2.79M ▼ | $-2.79M ▲ |
| Q4-2024 | $-1.73M ▲ | $-3.75M ▲ | $17.69K ▲ | $3.69M ▼ | $-42.03K ▲ | $-3.73M ▲ |
| Q3-2024 | $-2.24M | $-9.26M | $-17.69K | $3.74M | $-5.53M | $-9.27M |
CEO
James Rolke
Compensation Summary
(Year )
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
LINDEN ADVISORS LP
Shares:338.11K
Value:$2.77K
CLEAR STREET LLC
Shares:247.58K
Value:$2.03K
CLEAR STREET GROUP INC.
Shares:247.43K
Value:$2.03K
Summary
Showing Top 3 of 17